- Home
- XGN vs RFL Comparison
XGN vs RFL Comparison
Compare XGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XGN | RFL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.6M | 61.1M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XGN | RFL |
|---|---|---|
| Price | $2.85 | $1.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.14 | N/A |
| AVG Volume (30 Days) | ★ 328.2K | 104.9K |
| Earning Date | 03-10-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $13.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.75 | $1.12 |
| 52 Week High | $12.23 | $3.19 |
Technical Indicators
Market Signals| Indicator | XGN | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 43.70 |
| Support Level | N/A | $1.15 |
| Resistance Level | $3.89 | $1.61 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 9.64 | 11.54 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.